文献速递糖尿病

基线TBR对1型糖尿病严重低血糖的预测价值有限:六项临床试验分析

Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究基于六项临床试验的1433例1型糖尿病患者,评估基线CGM衍生的TBR1(<70 mg/dL)和TBR2(<54 mg/dL)对随访期间严重低血糖(SH)的预测能力。结果显示发生SH者基线TBR2和TBR1略高,但预测准确性有限,ROC曲线下面积仅0.62-0.65,无阈值能达到强区分度,提示需结合其他临床因素进行SH风险分层。

要点

  • 基线TBR1和TBR2对后续严重低血糖的预测价值有限。
  • 发生SH者基线TBR2和TBR1略高于未发生者,但差异幅度小。
  • TBR阈值敏感性随阈值升高而下降,无阈值达强区分度。

核心结论

  • 基线TBR1和TBR2对1型糖尿病患者随访期间严重低血糖的预测价值有限。
  • 无TBR阈值能达到强区分度,支持需整合其他临床因素进行SH风险分层。

研究设计与样本

  • 分析六项临床试验中1型糖尿病患者的基线CGM TBR水平与随访期间SH不良事件的关系。
  • 共纳入1433例参与者,中位年龄4-43岁,女性占50-62%,白人占83-96%。
  • 使用Wilcoxon秩和检验和Spearman相关性分析,并按性别、种族和年龄组分层。
  • 计算阈值1-5%的敏感性、特异性和假阳性率,并用ROC分析评估区分度。

主要发现

  • 六项试验中基线TBR2中位范围为0.1%至0.7%,TBR1为1.2%至4.1%。
  • 发生SH者基线TBR2为0.41% vs 0.32%(P=0.022),TBR1为2.58% vs 2.23%(P=0.044)。
  • TBR2敏感性从1% cutoff的48.9%降至5% cutoff的18.2%,特异性75.9-95.0%。
  • TBR1敏感性从81.8%降至44.3%,特异性29.6-77.7%。
  • ROC分析AUC:TBR2为0.62(95%CI 0.55-0.69),TBR1为0.65(95%CI 0.58-0.71)。

关键数值与推荐

  • TBR1定义为<70 mg/dL,TBR2定义为<54 mg/dL。
  • 评估的TBR阈值为1-5%。
  • TBR2在1% cutoff时敏感性48.9%、特异性75.9-95.0%;5% cutoff时敏感性18.2%。
  • TBR1在1% cutoff时敏感性81.8%、特异性29.6-77.7%;5% cutoff时敏感性44.3%。
  • ROC分析AUC:TBR2为0.62(95%CI 0.55-0.69),TBR1为0.65(95%CI 0.58-0.71)。

临床怎么用

  • 不应仅依赖基线TBR1或TBR2来预测1型糖尿病患者的严重低血糖风险。
  • 需结合其他临床因素进行SH风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether baseline continuous glucose monitoring (CGM)-derived time below range (TBR) metrics-TBR level 1 (TBR1) (<70 mg/dL) and TBR level 2 (TBR2) (<54 mg/dL)-predicts severe hypoglycemia (SH) during follow-up of individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Baseline CGM TBR levels and their association with SH adverse events during six clinical trials were analyzed using Wilcoxon rank sum tests and Spearman correlations. Analyses were stratified by sex, race, and age group. Sensitivity, specificity, and false-positive rates (FPRs) were calculated for thresholds (1-5%), and receiver operating characteristic (ROC) analysis assessed discrimination. RESULTS: Participants (n = 1,433; median age 4-43 years; 50-62% female sex; 83-96% White race) had a baseline median TBR2 range of 0.1% to 0.7% and TBR1 from 1.2% to 4.1% across the six clinical trials. Those who developed SH had slightly higher baseline TBR2 (0.41% vs. 0.32%; P = 0.022) and TBR1 (2.58% vs. 2.23%; P = 0.044). Predictive accuracy was limited: sensitivity of TBR2 fell from 48.9% at a 1% cutoff to 18.2% at 5% (specificity 75.9-95.0%), and TBR1 sensitivity declined from 81.8% to 44.3% (specificity 29.6-77.7%), with modest discrimination by ROC analysis (area under the curve = 0.62 [95% CI 0.55-0.69] for TBR2; and 0.65 [95% CI 0.58-0.71] for TBR1). CONCLUSIONS: Baseline TBR1 and TBR2 had limited predictive value for SH. No threshold achieved strong discrimination, a finding that supports the need to integrate additional clinical factors for SH risk stratification.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Montaser E, Williams C, Shah VN, et al. Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials. Diabetes Care. 2026. PMID: 41529164. doi:10.2337/dc25-2353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。